

Literaturverzeichnis

- 1.) Armitage, G. C. Development of a classification system for periodontal diseases and conditions. Northwest. Dent. 2000, 79, 31-35.
- 2.) Walter C, Lienert N, Kleinmann F: Therapie einer aggressiven Parodontitis – unter besonderer Berücksichtigung einer gerinnungshemmenden Medikation. Zahnärztl Mitt. 2008; 98: 40-45
- 3.) Guerrero, A., Griffiths, G. S., Nibali, L., Suvan, J., Moles, D. R., Laurell, L. & Tonetti, M. S. Adjunctive benefits of systemic amoxicillin and metronidazole in non-surgical treatment of generalized aggressive periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol. 2005, 32, 1096-1107.
- 4.) Van Winkelhoff, A. J., Rodenburg, J. P., Goene, R. J., Abbas, F., Winkel, E. G. & de, G. J. Metronidazole plus amoxycillin in the treatment of Actinobacillus actinomycetemcomitans associated periodontitis. J Clin Periodontol. 1989, 16, 128-131.
- 5.) <https://viamedici.thieme.de/lernmodul/549539/539520/Hämostase: Überblick - via medici>, Zugriff am 2.10.2025
- 6.) <https://de.wikipedia.org/wiki/Hämostase>, Zugriff am 2.10.2025
- 7.) Gerd Herold und Mitarbeiter. Innere Medizin. 2025. ISBN 978-3-9821166-4-8
- 8.) S3 Leitlinie (Langversion): Zahnärztliche Chirurgie unter Antikoagulanzen/Thrombozytenaggregationshemmern. AWMF-Registernummer: 083-018, Stand: August 2017, Gültig bis: August 2020 via. www.dgzmk.de, Zugriff am 1. 10. 2025
- 9.) Schindler C, Kirch W: Zahnärztl. Mitteilungen 2009, 99 (2). 42-44.
- 10.) Schwaiger M, Wallner J, Zemmann W, Aichner S, Zrnc T, Metzler P: Application of tranexamic acid within the field of dentistry (in German). SWISS DENTAL JOURNAL SSO 2021: 131: 827–829.
- 11.) <https://de.wikipedia.org/wiki/Wasserstoffperoxid>, Zugriff am 3.10.2025
- 12.) <https://de.wikipedia.org/wiki/Acetylsalicylsäure>, Zugriff am 3.10.2025
- 13.) Cordes V, Pischon N, Riess H, Dommisch H. Neue orale Antikoagulanzen in der zahnärztlichen Praxis. Parodontologie 2016; 27(1):9-15.
- 14.) Nesse W, Abbas F, van der Ploeg I, Spijkervet FK, Dijkstra PU, Vissink A. Periodontal inflamed surface area: quantifying inflammatory burden. J Clin Periodontol. 2008 Aug;35(8):668-73.

- 15.) Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Berglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60.
- 16.) Stein JM, Yekta-Michael SS, Schittenhelm F, Reichert S, Kupietz D, Dommisch H, Kasaj A, Wied S, Vela OC, Stratul SI. Comparison of three full-mouth concepts for the non-surgical treatment of stage III and IV periodontitis: A randomized controlled trial. J Clin Periodontol. 2021 Dec;48(12):1516-1527.
- 17.) <https://salk.at/analysen/>, Zugriff am 3.10.2025
- 18.) <https://de.wikipedia.org/wiki/Glanzmann-Thrombasthenie>, Zugriff am 3.10.2025
- 19.) <https://navigation-im-pvz.de/2025/03/08/mehrfach-chronisch-krank-multimorbidit%C3%A4t-ist-im-alter-die-regel/>, Zugriff am 4.10.2025
- 20.) Walter C, Büttel L, Weiger R. Localized alveolar ridge augmentation using a two-step approach with different soft tissue grafts: a clinical report. J Contemp Dent Pract. 2008 May 1;9(4):99-106.
- 21.) <https://de.wikipedia.org/wiki/Fibrinolyse>, Zugriff am 5.10.2025
- 22.) <https://webde.stago.com/haemostase/>, Zugriff am 5.10.2025
- 23.) <https://herzstiftung.de/service-und-aktuelles/presse/pressemitteilungen/blutgerinnung-verhindern-leitfaden>, Zugriff am 5.10.2025
- 24.) Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, Mealey BL, Papapanou PN, Sanz M, Tonetti MS. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Clin Periodontol. 2018 Jun;45 Suppl 20:S1-S8.
- 25.) Strauch KA, Robbins MR. Scaling and Root Planing in a Patient with Atherosclerosis, Arrhythmia, and Anticoagulation. Dent Clin North Am. 2023 Jul;67(3):393-396.
- 26.) Morgado-Sevillano D, Rodríguez-Molinero J, García-Bravo C, Peña-Cardelles JF, Ruiz-Roca JA, García-Guerrero I, Gómez-de Diego R. Oral surgery considerations in patients at high-risk of complications related to drug intake: A systematic review. Saudi Dent J. 2024 Dec;36(12):1503-1508.

- 27.) Gebrauchsinformation: Information für Anwender Eliquis 5mg Filmtabletten Apixaban, Stand, Juli 2025
- 28.) Greinacher A. Heparininduzierte Thrombozytopenie Dtsch Arztebl 2003; 100: A 2220–2229 [Heft 34–35]
- 29.) Graziani F, Cei S, Orlandi M, Gennai S, Gabriele M, Filice N, Nisi M, D'Aiuto F. Acute-phase response following full-mouth versus quadrant non-surgical periodontal treatment: A randomized clinical trial. J Clin Periodontol. 2015 Sep;42(9):843-852
- 30.) Hoang T, Dowdy RAE. Review of Inherited Coagulation Disorders. Anesth Prog. 2024 Jul 8;71(2):87-95.
- 31.) Gralnick HR, Sultan Y, Collier BS. Von Willebrand's disease: combined qualitative and quantitative abnormalities. N Engl J Med. 1977 May 5;296(18):1024-30.
- 32.) Santoshi RK, Patel R, Patel NS, Bansro V, Chhabra G. A Comprehensive Review of Thrombocytopenia With a Spotlight on Intensive Care Patients. Cureus. 2022 Aug 5;14(8):e27718.
- 33.) Mladěnka P, Macáková K, Kujovská Krčmová L, Javorská L, Mrštná K, Carazo A, Protti M, Remião F, Nováková L; OEMONOM researchers and collaborators. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev. 2022 Mar 10;80(4):677-698.
- 34.) Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016 Jun 2;2:16037.
- 35.) Caldwell, Stephen M.D., F.A.A.S.L.D.*;1; Carlini, Lauren Evers M.D.1. Coagulation Homeostasis in Liver Disease. Clinical Liver Disease 16(4):p 137-141, October 2020.
- 36.) Harrison MF. The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. West J Emerg Med. 2018 Sep;19(5):863-871.
- 37.) Dézsi CA, Dézsi BB, Dézsi AD. Management of dental patients receiving antiplatelet therapy or chronic oral anticoagulation: A review of the latest evidence. Eur J Gen Pract. 2017 Dec;23(1):196-201. doi: 10.1080/13814788.2017.1350645.
- 38.) Botero JP, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W, Di Paola J; ClinGen Platelet Disorder

Variant Curation Expert Panel. Glanzmann thrombasthenia: genetic basis and clinical correlates. *Haematologica*. 2020 Apr;105(4):888-894.

- 39.) Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: Biology and dental implications. *Med Oral Patol Oral Cir Bucal*. 2013 May 1;18 (3):e461-72.
- 40.) Abdullah WA, Khalil H. Dental extraction in patients on warfarin treatment. *Clin Cosmet Investig Dent*. 2014 Aug 19;6:65-9.
- 41.) Bakathir AA. Minor Oral Surgery Procedures in Patients Taking Warfarin: A 5-year retrospective study at Sultan Qaboos University Hospital, Sultanate of Oman. *Sultan Qaboos Univ Med J*. 2009 Dec;9(3):279-86.
- 42.) Ozyilmaz OD, Gundogdu S, Alkan A. Attitude and practice of dentists in patients taking oral antiplatelet and anticoagulant medications. *BMC Oral Health*. 2025 Apr 20;25(1):606.
- 43.) Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. *Semin Thromb Hemost*. 1997;23(4):349-56.
- 44.) Fontana P, Zufferey A, Daali Y, Reny JL. Antiplatelet therapy: targeting the TxA2 pathway. *J Cardiovasc Transl Res*. 2014 Feb;7(1):29-38.
- 45.) Rucker D, Dhamoon AS. Physiology, Thromboxane A2. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539817/>
- 46.) Oprea AD, Popescu WM. P2Y₁₂ Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? *Cardiol Res Pract*. 2013;2013:195456.
- 47.) Koski R, Kennedy B. Comparative Review of Oral P2Y₁₂ Inhibitors. *P T*. 2018 Jun;43(6):352-357. PMID: 29896034; PMCID: PMC5969212.
- 48.) Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. *Br J Pharmacol*. 2010 Feb 1;159(3):502-17.

- 49.) Shixuan Liu, Guomin Shen, Weikai Li, Structural and cellular basis of vitamin K antagonism, *Journal of Thrombosis and Haemostasis*, Volume 20, Issue 9, 2022, Pages 1971-1983, ISSN 1538-7836
- 50.) Lindhoff-Last, Edelgard & Birschmann, Ingvild & Bidentharn, Antonia & Kuhn, Joachim & Lindau, Simone & Konstantinides, Stavros & Grottke, Oliver & Nowak-Göttl, Ulrike & Lucks, Jessica & Zydek, B. & von Heymann, Christian & Sümnick, A. & Beyer-westendorf, Jan & Schellong, Sebastian & Meybohm, Patrick & Greinacher, Andreas & Herrmann, Eva. (2022). Pharmacokinetics of Phenprocoumon in Emergency Situations—Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry). *Pharmaceuticals*. 15. 1437. 10.3390/ph15111437.
- 51.) Altioek, E; Marx, N. Oral Anticoagulation: Update on anticoagulation with vitamin K antagonists and non–vitamin K–dependent oral anticoagulants. *Dtsch Arztebl Int* 2018; 115: 776-83.
- 52.) Chan, Noel et al., Direct oral anticoagulants: evidence and unresolved issues
The Lancet, Volume 396, Issue 10264, 1767 – 1776
- 53.) Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). *Biomedicines*. 2021 Apr 21;9(5):445. doi: 10.3390/biomedicines9050445. PMID: 33919121; PMCID: PMC8143174.
- 54.) Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. *Chest*. 2001 Jan;119(1 Suppl):64S-94S.
- 55.) Jack Hirsh, Theodore E. Warkentin, Stephen G. Shaughnessy, Sonia S. Anand, Jonathan L. Halperin, Robert Raschke, Christopher Granger, E. Magnus Ohman, James E. Dalen, Heparin and Low-Molecular-Weight Heparin

Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety, Chest, Volume 119, Issue 1, Supplement, 2001, Pages 64S-94S, ISSN 0012-3692

- 56.) Patel P, Varacallo MA. Low-Molecular-Weight Heparin (LMWH) [Updated 2025 Mar 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK525957/>
- 57.) Hirsh, J., Anand, S. S., Halperin, J. L., & Fuster, V. (2001). *Guide to Anticoagulant Therapy: Heparin*. *Circulation*, 103(24), 2994.